Metabolic Health & Body Composition
Retatrutide
Investigational — not yet approved
An investigational triple-agonist peptide currently in Phase 3 trials. Listed here for educational transparency — not yet legally available outside clinical trials.
Overview
Retatrutide is a once-weekly investigational triple agonist of GIP, GLP-1, and glucagon receptors, currently in Eli Lilly's TRIUMPH Phase 3 program. As of May 2026 it is not FDA-approved and is not legally available for clinical use outside formal trials. The first Phase 3 readout (TRIUMPH-4, December 11, 2025) reported that participants on the 12 mg dose lost an average of 28.7% of body weight (approximately 32.3 kg / 71.2 lb) at 68 weeks in adults with obesity and knee osteoarthritis. We include retatrutide on the menu only as an educational entry, not as a service offered.
Evidence: investigational only
In consultation, clients often ask
The fact that retatrutide cannot be legally prescribed outside FDA-approved clinical trials as of May 2026.
The realistic timeline — Lilly is expected to file an NDA in late 2026 or early 2027, with potential approval in late 2027 at the earliest.
Regulatory & sourcing
Investigational only. Not FDA-approved. Not available through any legitimate compounding pathway. Listed here for educational transparency, not as a service. Any product marketed as retatrutide outside a registered clinical trial is unregulated and not sourced or recommended by Jaed Aesthetics.
References
Eli Lilly and Company. TRIUMPH-4 Phase 3 topline results press release, December 11, 2025.
Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389:514–526.
Please read
Peptide therapy at Jaed Aesthetics is offered as a private wellness consultation service. None of the peptides discussed on this menu are FDA-approved for the wellness areas described, and some are investigational or available only through compounding pharmacies operating under FDA Sections 503A or 503B. Several peptides on this menu have primarily pre-clinical or animal evidence and limited published human data; we note this honestly under each entry. Any decision to proceed, the specific peptide selected, route of administration, dosing, monitoring, and pricing are determined one-on-one with our nurse practitioner during consultation. Nothing on this page constitutes medical advice, a diagnosis, or a treatment recommendation.
By consultation
Schedule a peptide consultation, in the basin.
Pricing, availability, and treatment plans are determined one-on-one. Bring your goals — we'll work the plan from there.